Description: Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.
Home Page: www.edgewisetx.com
EWTX Technical Analysis
3415 Colorado Avenue
Boulder,
CO
80303
United States
Phone:
303 735 8373
Officers
| Name | Title |
|---|---|
| Dr. Kevin Koch Ph.D. | Pres, CEO & Director |
| Dr. Badreddin Edris Ph.D. | Co-Founder & Independent Director |
| Dr. Behrad Derakhshan Ph.D. | Chief Bus. Officer |
| Dr. Joanne M. Donovan M.D., Ph.D. | Chief Medical Officer |
| Dr. Alan J. Russell Ph.D. | Co-Founder, Chief Scientific Officer & Director |
| Mr. R. Michael Carruthers | Chief Financial Officer |
| Mr. John R. Moore | Gen. Counsel |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 3.173 |
| Price-to-Book MRQ: | 1.3626 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-03-26 |
| Fiscal Year End: | December |
| Full Time Employees: | 50 |